Typicality: | 0.408 |
Saliency: | 0.371 |
for the first time | 39 | manner |
in phase | 13 | temporal |
to prevent the hormone | 3 | purpose |
researcher → test → experimental drug | 26 |
researcher → use → experimental drug | 7 |
researcher → test → experimental drugs | 3 |
negative | neutral | positive |
0.078 | 0.835 | 0.087 |
Raw frequency | 36 |
Normalized frequency | 0.371 |
Modifier score | 0.500 |
Perplexity | 129.327 |